

Protocol Registration Receipt
07/10/2014

Grantor: CDER IND/IDE Number: 106,616 Serial Number: 0139

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

This study has been completed.

Sponsor:	GlaxoSmithKline
Collaborators:	
Information provided by (Responsible Party):	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT01316913

► Purpose

This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder via a Novel Dry Powder Inhaler and tiotropium via HandiHaler when administered once-daily over a 24-week treatment period in subjects with chronic obstructive pulmonary disease (COPD). Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to10 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 26 weeks. The primary measure of efficacy is clinic visit trough (pre-bronchodilator

and pre-dose) forced expiratory volume in one second (FEV1) on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, and clinical laboratory tests.

Condition	Intervention	Phase
Pulmonary Disease, Chronic Obstructive	Drug: GSK573719/GW642444 125/25 Drug: GSK573719/GW642444 62.5/25 Drug: GSK573719 Drug: tiotropium bromide	Phase 3

Study Type: Interventional

Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Safety/Efficacy Study

Official Title: A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measure:

- Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169 [Time Frame: Baseline and Day 169]
[Designated as safety issue: No]

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (i.e., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline, smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat.

Secondary Outcome Measures:

- Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168 [Time Frame: Baseline and Day 168] [Designated as safety issue: No]

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 84, and Day 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes [min] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 minutes, 30 minutes, 1 hour, 3 hours, and 6 hours. Change from BL at a particular visit was calculated as WM at that visit minus BL. Analysis was

performed using a repeated measures model with covariates of treatment, BL (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), smoking status, center group, day, and day by BL and day by treatment interactions.

Other Pre-specified Outcome Measures:

- Change From Baseline (BL) in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24 [Time Frame: Baseline and Week 24]
[Designated as safety issue: No]

The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day's activities. The daily score is computed as the mean of the scores on the 13 items (≥ 7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (≥ 4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.

Enrollment: 872

Study Start Date: March 2011

Study Completion Date: April 2012

Primary Completion Date: April 2012

Arms	Assigned Interventions
Experimental: GSK573719/GW642444 125/25 125/25 mcg once-daily	Drug: GSK573719/GW642444 125/25 125/25 mcg once-daily Other Names: GSK573719/vilanterol trifenate
Experimental: GSK573719/GW642444 62.5/25 62.5/25 mcg once-daily	Drug: GSK573719/GW642444 62.5/25 62.5/25 mcg once-daily Other Names: GSK573719/vilanterol trifenate
Experimental: GSK573719 125 mcg once-daily	Drug: GSK573719 125 mcg once-daily Other Names: GSK573719

Arms	Assigned Interventions
Active Comparator: tiotropium bromide 18 mcg once-daily	Drug: tiotropium bromide 18 mcg once-daily Other Names: tiotropium bromide

This is a 24-week, Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study. Eligible subjects will be randomized to GSK573719/GW642444 125/25mcg, GSK573719/GW642444 62.5/25mcg, GSK573719 125mcg, or tiotropium treatment groups in a 1:1:1:1 ratio. Treatments will be administered once-daily in the morning by inhalation using a Novel Dry Powder Inhaler (Novel DPI) and HandiHaler. There will be a total of 9 study clinic visits conducted on an outpatient basis. Subjects who meet the eligibility criteria at Screening (Visit 1) will complete a 7 to 10 day run-in period followed by a 24-week treatment period. Clinic visits will be at Screening, Randomization (Day 1), Day 2, after 4, 8, 12, 16, and 24-weeks of treatment, and 1 day after the Week 24 Visit (also referred as Treatment Day 169). A follow-up contact for adverse assessment will be conducted by telephone approximately 7 days after Visit 9 or the Early Withdrawal Visit. The total duration of subject participation, including follow-up will be approximately 26 weeks. All subjects will be provided with albuterol/salbutamol for use on an “as-needed” basis throughout the run-in and study treatment periods. At screening, pre-bronchodilator spirometry testing will be followed by post-albuterol/salbutamol spirometry testing. Post-albuterol/salbutamol FEV1 and FEV1/forced vital capacity (FVC) values will be used to determine subject eligibility. To further characterize bronchodilator responsiveness, post-ipratropium testing will be conducted following completion of post-albuterol/salbutamol spirometry. Spirometry will be conducted at each post-randomization clinic visit. Six hour post-dose serial spirometry will be conducted at Visits 2, 6, and 8. Trough spirometry will be obtained 23 and 24 hours after the previous day’s dose of blinded study medication at Visits 3 to 9. All subjects will be provided with an electronic diary (eDiary) for completion daily in the morning and the evening throughout the run-in and treatment periods. Subjects will use the eDiary to record peak expiratory flow (PEF) each morning, dyspnea scores using the Shortness of Breath with Daily Activities instrument (SOBDA), daily use of supplemental albuterol/salbutamol as either puffs/day from a metered-dose inhaler (MDI) and/or nebulas used per day, and any healthcare contacts related to COPD. Additional assessments of dyspnea will be obtained using the Baseline and Transition Dyspnea Index (BDI/TDI) which is an interviewer based instrument. At Visit 2, the severity of dyspnea at baseline will be assessed using the BDI. At subsequent visits (Visits 4, 6, and 8) change from baseline will be assessed using the TDI. General health status will be evaluated using the subject-completed EQ-5D questionnaire at Visits 2, 4, 6, and 8. Disease specific health status will be evaluated using the subject-completed St. George’s Respiratory Questionnaire (SGRQ) at Visits 2, 4, 6, and 8, and the subject-completed COPD Assessment Test (CAT) at Visits 2, 6, and 8. The occurrence of adverse events will be evaluated throughout the study beginning at Visit 2. SAEs will be collected over the same time period as for AEs. However, any SAEs assessed as related to study participation (e.g., study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK concomitant medication, will be recorded from the time a subject consents to participate in the study up to and including any follow up contact. Additional safety assessments of vital signs (blood pressure and pulse rate), 12-lead ECGs and standard clinical laboratory tests (hematology and chemistry) will be obtained at selected clinic visits.

Eligibility

Ages Eligible for Study: 40 Years and older

Genders Eligible for Study: Both

Inclusion Criteria:

- outpatient
- signed and dated written informed consent
- 40 years of age or older
- male and female subjects
- COPD diagnosis
- at least 10 pack-year smoking history
- post-albuterol/salbutamol FEV1/FVC ratio of <0.70 and post-albuterol/salbutamol FEV1 of less than or equal to 70% predicted normal values
- score of greater than or equal to 2 on the Modified Medical Research Council Dyspnea Scale (mMRC)

Exclusion Criteria:

- women who are pregnant or lactating or are planning on becoming pregnant during the study
- current diagnosis of asthma
- other respiratory disorders other than COPD
- other diseases/abnormalities that are uncontrolled including cancer not in remission for at least 5 years
- chest x-ray or CT scan with clinically significant abnormalities not believed to be due to COPD
- hypersensitivity to anticholinergics, beta-agonists, lactose/milk protein or magnesium stearate or medical conditions associated with inhaled anticholinergics
- hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1
- lung volume reduction surgery within 12 months prior to Visit 1
- abnormal and clinically significant ECG at Visit 1
- significantly abnormal finding from laboratory tests at Visit 1
- unable to withhold albuterol/salbutamol at least 4 hours prior to spirometry at each visit
- use of depot corticosteroids within 12 weeks of Visit 1
- use of oral or parenteral corticosteroids, antibiotics for lower respiratory tract infection, or cytochrome P450 3A4 inhibitors, within 6 weeks of Visit 1
- use of long-acting beta-agonist (LABA)/inhaled corticosteroid (ICS) product if LABA/ICS therapy is discontinued within 30 days of Visit 1
- use of ICS at a dose of $>1000\text{mcg/day}$ of fluticasone propionate or equivalent within 30 days of Visit 1
- initiation or discontinuation of ICS within 30 days of Visit 1
- use of tiotropium or roflumilast within 14 days of Visit 1
- use of theophyllines, oral leukotriene inhibitors, long-acting oral beta-agonists, or inhaled long-acting beta-agonists within 48 hours of Visit 1
- short-acting oral beta-agonists within 12 hours of Visit 1
- use of LABA/ICS combination products only if discontinuing LABA therapy and switching to ICS monotherapy within 48 hours of Visit 1 for the LABA component

- use of sodium cromoglycate or nedocromil sodium within 24 hours of Visit 1
- use of inhaled short-acting beta-agonists, inhaled short-acting anticholinergics, or inhaled short-acting anticholinergic/short-acting beta-agonist combination products within 4 hours of Visit 1
- use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer)
- long-term oxygen therapy prescribed for >12 hours per day
- regular use of nebulized short-acting bronchodilators
- participation in acute phase of pulmonary rehabilitation program
- known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1
- anyone affiliated with the investigator site (e.g., investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member)
- previous exposure to GSK573719, GSK573719/GW642444 combination, GW642444 (vilanterol), or fluticasone furoate/GW642444 combination

Contacts and Locations

Locations

United States, Alabama

GSK Investigational Site

Jasper, Alabama, United States, 35501

GSK Investigational Site

Mobile, Alabama, United States, 36608

United States, California

GSK Investigational Site

Huntington Beach, California, United States, 92647

GSK Investigational Site

Los Angeles, California, United States, 90048

United States, Florida

GSK Investigational Site

Clearwater, Florida, United States, 33765

GSK Investigational Site

Ormond Beach, Florida, United States, 32174

United States, Georgia

GSK Investigational Site

Lawrenceville, Georgia, United States, 30046

United States, Kansas

GSK Investigational Site

Topeka, Kansas, United States, 66606

United States, Kentucky

GSK Investigational Site

Madisonville, Kentucky, United States, 42431

United States, Louisiana

GSK Investigational Site

Lafayette, Louisiana, United States, 70503

GSK Investigational Site

New Orleans, Louisiana, United States, 70115

United States, Missouri

GSK Investigational Site

St. Louis, Missouri, United States, 63141

United States, North Carolina

GSK Investigational Site

Charlotte, North Carolina, United States, 28207

GSK Investigational Site

Elizabeth City, North Carolina, United States, 27909

United States, Ohio

GSK Investigational Site

Cincinnati, Ohio, United States, 45231

United States, Oregon

GSK Investigational Site

Medford, Oregon, United States, 97504

United States, Pennsylvania

GSK Investigational Site

Beaver, Pennsylvania, United States, 15009

United States, South Carolina

GSK Investigational Site

Easley, South Carolina, United States, 29640

GSK Investigational Site

Spartanburg, South Carolina, United States, 29303

United States, West Virginia

GSK Investigational Site

Morgantown, West Virginia, United States, 26505

Argentina

GSK Investigational Site

Buenos Aires, Argentina, C1425BEN

GSK Investigational Site

Ciudad Autónoma de Buenos Aires, Argentina, C1426ABP

GSK Investigational Site

Buenos Aires, Buenos Aires, Argentina, C1424BSF

GSK Investigational Site

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1028AAP

GSK Investigational Site

Mendoza, Mendoza, Argentina, M5500CCG

Australia, New South Wales

GSK Investigational Site

Concord, New South Wales, Australia, 2139

Australia, Queensland

GSK Investigational Site

Cairns, Queensland, Australia, 4870

GSK Investigational Site

Carina Heights, Queensland, Australia, 4152

GSK Investigational Site

Kippa Ring, Queensland, Australia, 4021

Australia, South Australia

GSK Investigational Site

Adelaide, South Australia, Australia, 5000

GSK Investigational Site

Daw Park, South Australia, Australia, 5041

Australia, Victoria

GSK Investigational Site

Frankston, Victoria, Australia, 3199

GSK Investigational Site

Parkville, Victoria, Australia, 3050

Australia, Western Australia

GSK Investigational Site

Nedlands, Western Australia, Australia, 6009

GSK Investigational Site

Nedlands, Western Australia, Australia, 6009

Canada, Manitoba

GSK Investigational Site

Winnipeg, Manitoba, Canada, R2H 2A6

GSK Investigational Site

Winnipeg, Manitoba, Canada, R2K 3S8

Canada, Newfoundland and Labrador

GSK Investigational Site

Bay Roberts, Newfoundland and Labrador, Canada, A0A 1G0

Canada, Nova Scotia

GSK Investigational Site

Truro, Nova Scotia, Canada, B2N 1L2

Canada, Ontario

GSK Investigational Site

Mississauga, Ontario, Canada, L5M 2V8

GSK Investigational Site

Sudbury, Ontario, Canada, P3E 1H5

GSK Investigational Site

Toronto, Ontario, Canada, M5T 3A9

Canada, Quebec

GSK Investigational Site

Gatineau, Quebec, Canada, J8Y 6S8

GSK Investigational Site

Quebec, Quebec, Canada, G1V 4G5

GSK Investigational Site

St-Romulad, Quebec, Canada, G6W 5M6

Chile

GSK Investigational Site

Santiago, Chile, 8380453

GSK Investigational Site

Puerto Montt, Región De Los Lagos, Chile, 5480000

GSK Investigational Site

Santiago, Región Metro De Santiago, Chile, 7601003

GSK Investigational Site

Santiago, Región Metro De Santiago, Chile, 7500710

GSK Investigational Site

Santiago, Región Metro De Santiago, Chile, 7500800

GSK Investigational Site

Santiago, Región Metro De Santiago, Chile, 7500551

GSK Investigational Site

Talca, Región Metro De Santiago, Chile, 3460001

Germany

GSK Investigational Site

Schwetzingen, Baden-Wuerttemberg, Germany, 68723

GSK Investigational Site

Aschaffenburg, Bayern, Germany, 63739

GSK Investigational Site

Berlin, Berlin, Germany, 12099

GSK Investigational Site

Berlin, Berlin, Germany, 10629

GSK Investigational Site

Oranienburg, Brandenburg, Germany, 16515

GSK Investigational Site

Ruedersdorf, Brandenburg, Germany, 15562

GSK Investigational Site

Schwedt, Brandenburg, Germany, 16303

GSK Investigational Site

Hamburg, Hamburg, Germany, 22335

GSK Investigational Site

Frankfurt, Hessen, Germany, 60389

GSK Investigational Site

Kassel, Hessen, Germany, 34121

GSK Investigational Site

Wolfenbuettel, Niedersachsen, Germany, 38300

GSK Investigational Site
Dueren, Nordrhein-Westfalen, Germany, 52349

GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45359

GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45355

GSK Investigational Site
Koblenz, Rheinland-Pfalz, Germany, 56068

GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55116

GSK Investigational Site
Leipzig, Sachsen, Germany, 04207

Korea, Republic of

GSK Investigational Site
Bucheon-si,, Korea, Republic of, 420-767

GSK Investigational Site
Cheongju, Chungcheongbuk-do, Korea, Republic of, 361-711

GSK Investigational Site
Daegu, Korea, Republic of, 705-717

GSK Investigational Site
Incheon, Korea, Republic of, 400-711

GSK Investigational Site
Incheon, Korea, Republic of, 405-760

GSK Investigational Site
Kangwon-do, Korea, Republic of, 220-701

GSK Investigational Site
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707

GSK Investigational Site
Seoul, Korea, Republic of, 130-702

GSK Investigational Site
Seoul, Korea, Republic of, 100-032

GSK Investigational Site
Seoul, Korea, Republic of, 143-729

GSK Investigational Site
Seoul, Korea, Republic of, 110-744

GSK Investigational Site

Seoul, Korea, Republic of, 156-707

GSK Investigational Site

Seoul, Korea, Republic of, 130-848

GSK Investigational Site

Seoul, Korea, Republic of

GSK Investigational Site

Seoul, Korea, Republic of, 136-705

GSK Investigational Site

Seoul, Korea, Republic of, 152-703

GSK Investigational Site

Suwon, Kyonggi-do, Korea, Republic of, 443-721

Mexico

GSK Investigational Site

Mexico, Mexico, 14000

GSK Investigational Site

Durango, Durango, Mexico, 34080

GSK Investigational Site

Zapopan, Jalisco, Mexico, 45040

GSK Investigational Site

Monterrey, Nuevo León, Mexico, 64020

Romania

GSK Investigational Site

Constanta, Romania, 900002

GSK Investigational Site

Ploiesti, Romania, 100379

GSK Investigational Site

Targoviste, Romania, 130086

South Africa

GSK Investigational Site

Bloemfontein, South Africa, 9301

GSK Investigational Site

Boksburg North, South Africa, 1459

GSK Investigational Site

Die Wilgers, South Africa, 0041
GSK Investigational Site
Durban, South Africa, 4091
GSK Investigational Site
Gatesville, South Africa, 7764
GSK Investigational Site
Groenkloof, South Africa, 0181
GSK Investigational Site
Pretoria, South Africa, 0002
GSK Investigational Site
Thabazimbi, South Africa, 0380

Investigators

Study Director: GSK Clinical Trials GlaxoSmithKline

More Information

Responsible Party: GlaxoSmithKline
Study ID Numbers: 113374
Health Authority: United States: Food and Drug Administration

Study Results

Participant Flow

Pre-Assignment Details

Participants (par.) who met eligibility criteria at Screening (Visit 1) completed a 7- to10-day run-in period and were then randomized to a 24-week treatment period. A total of 1191 par. were screened; 872 par. were randomized and 869 par. entered the treatment period.

Reporting Groups

	Description
UMEC 125 µg QD	Participants received umeclidinium bromide (UMEC) 125 micrograms (µg) once daily (QD) via a dry powder inhaler (DPI) and placebo QD via a HandiHaler in the morning for 24 weeks.
UMEC/VI 62.5/25 µg QD	Participants received umeclidinium bromide/vilanterol (UMEC/VI) 62.5/25 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
UMEC/VI 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
TIO18 µg QD	Participants received tiotropium bromide (TIO) 18 µg QD via a HandiHaler and placebo QD via a DPI in the morning for 24 weeks.

Overall Study

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
Started	222	217	215	215
Completed	165	163	166	176
Not Completed	57	54	49	39
Adverse Event	17	20	15	11
Lack of Efficacy	22	12	9	13
Protocol Violation	1	4	4	1
Protocol-defined Stopping Criteria	7	8	11	6
Lost to Follow-up	0	1	0	2

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
Withdrawal by Subject	10	9	10	6

Baseline Characteristics

Reporting Groups

	Description
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
UMEC/VI 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
TIO18 µg QD	Participants received TIO 18 µg QD via a HandiHaler and placebo QD via a DPI in the morning for 24 weeks.

Baseline Measures

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD	Total
Number of Participants	222	217	215	215	869
Age, Continuous [units: Years] Mean (Standard Deviation)	64.5 (8.33)	65.0 (8.62)	63.8 (8.51)	65.2 (8.30)	64.6 (8.44)
Gender, Male/Female					

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD	Total
[units: Participants]					
Female	74	77	67	62	280
Male	148	140	148	153	589
Race/Ethnicity, Customized [units: participants]					
African American/African Heritage	6	8	9	8	31
Asian - East Asian Heritage	35	34	36	34	139
Asian - South East Asian Heritage	2	1	1	2	6
Native Hawaiian or other Pacific Islander	0	1	0	0	1
White - Arabic/North African Heritage	1	0	0	0	1
White - White/Caucasian/European Heritage	169	163	160	163	655
White - Mixed Race	0	1	0	0	1
Mixed Race	9	9	9	8	35

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169
Measure Description	FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (i.e., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline, smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat.
Time Frame	Baseline and Day 169
Safety Issue?	No

Analysis Population Description

ITT Population: all participants randomized to treatment who received at least one dose of randomized study drug in the Treatment Period. Participants analyzed are those with data available at the presented time point; but, all participants without missing covariate information and with ≥ 1 post-Baseline measurement were included in the analysis.

Reporting Groups

	Description
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.

	Description
UMEC/VI 125/25 QD	Participants received UMEC/VI 125/25 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
TIO18 µg QD	Participants received TIO 18 µg QD via a HandiHaler and placebo QD via a DPI in the morning for 24 weeks.

Measured Values

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 QD	TIO18 µg QD
Number of Participants Analyzed	163	161	164	175
Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169 [units: Liters] Least Squares Mean (Standard Error)	0.186 (0.0178)	0.208 (0.0180)	0.223 (0.0179)	0.149 (0.0176)

Statistical Analysis 1 for Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169

Groups	UMEC 125 µg QD, UMEC/VI 62.5/25 µg QD
Method	Mixed Models Analysis
P-Value	0.377
Other Estimated Parameter [Least squares mean difference]	0.022
95% Confidence Interval	-0.027 to 0.072

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for

statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least squares mean difference=UMEC/VI 62.5/25 µg minus UMEC 125 µg.

Statistical Analysis 2 for Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169

Groups	UMEC/VI 62.5/25 µg QD, TIO18 µg QD
Method	Mixed Models Analysis
P-Value	0.018
Other Estimated Parameter [Least squares mean difference]	0.060
95% Confidence Interval	0.010 to 0.109

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

nominal p-value

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least squares mean difference=UMEC/VI 62.5/25 µg minus TIO 18 µg.

Statistical Analysis 3 for Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169

Groups	UMEC 125 µg QD, UMEC/VI 125/25 QD
Method	Mixed Models Analysis

P-Value	0.142
Other Estimated Parameter [Least squares mean difference]	0.037
95% Confidence Interval	-0.012 to 0.087

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least squares mean difference=UMEC/VI 125/25 µg minus UMEC 125 µg.

Statistical Analysis 4 for Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169

Groups	UMEC/VI 125/25 QD, TIO18 µg QD
Method	Mixed Models Analysis
P-Value	0.003
Other Estimated Parameter [Least squares mean difference]	0.074
95% Confidence Interval	0.025 to 0.123

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least squares mean difference=UMEC/VI 125/25 µg minus TIO 18 µg.

2. Secondary Outcome Measure:

Measure Title	Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168
Measure Description	FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 84, and Day 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes [min] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 minutes, 30 minutes, 1 hour, 3 hours, and 6 hours. Change from BL at a particular visit was calculated as WM at that visit minus BL. Analysis was performed using a repeated measures model with covariates of treatment, BL (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), smoking status, center group, day, and day by BL and day by treatment interactions.
Time Frame	Baseline and Day 168
Safety Issue?	No

Analysis Population Description

ITT Population. Par. analyzed are those with data available at the presented time point; but, all par. without missing covariate information and with ≥ 1 post-Baseline measurement were included in the analysis.

Reporting Groups

	Description
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
UMEC/VI 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
TIO18 µg QD	Participants received TIO 18 µg QD via a HandiHaler and placebo QD via a DPI in the morning for 24 weeks.

Measured Values

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
Number of Participants Analyzed	161	161	164	172
Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168 [units: Liters] Least Squares Mean (Standard Error)	0.206 (0.0167)	0.276 (0.0168)	0.282 (0.0167)	0.180 (0.0165)

3. Other Pre-specified Outcome Measure:

Measure Title	Change From Baseline (BL) in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24
Measure Description	The newly developed SOBDA questionnaire assesses dyspnea or

	<p>shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day's activities. The daily score is computed as the mean of the scores on the 13 items (≥ 7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (≥ 4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.</p>
Time Frame	Baseline and Week 24
Safety Issue?	No

Analysis Population Description

ITT Population. Participants analyzed are those with data available at the presented time point; but, all participants without missing covariate information and with ≥ 1 post-Baseline measurement were included in the analysis.

Reporting Groups

	Description
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
UMEC/VI 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.

	Description
TIO18 µg QD	Participants received TIO 18 µg QD via a HandiHaler and placebo QD via a DPI in the morning for 24 weeks.

Measured Values

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
Number of Participants Analyzed	104	114	117	121
Change From Baseline (BL) in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24 [units: scores on a scale] Least Squares Mean (Standard Error)	-0.19 (0.041)	-0.29 (0.040)	-0.33 (0.040)	-0.21 (0.040)

Reported Adverse Events

Reporting Groups

	Description
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
UMEC/VI 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI and placebo QD via a HandiHaler in the morning for 24 weeks.
TIO18 µg QD	Participants received TIO 18 µg QD via a HandiHaler and placebo QD via a DPI in the morning for 24 weeks.

Time Frame

On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the end of treatment (up to 24 weeks).

Additional Description

On-treatment SAEs and non-serious AEs were reported for members of the ITT Population, comprised of all participants randomized to treatment who received at least one dose of randomized study drug in the Treatment Period.

Serious Adverse Events

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
Total # participants affected/at risk	15/222 (6.76%)	22/217 (10.14%)	15/215 (6.98%)	9/215 (4.19%)
Blood and lymphatic system disorders				
Anaemia † ^A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				
Cardiac disorders				
Angina unstable † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Coronary artery disease † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	2/215 (0.93%)	0/215 (0%)

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
# events				
Myocardial infarction † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Gastrointestinal disorders				
Gastritis † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	1/215 (0.47%)	0/215 (0%)
# events				
Upper gastrointestinal haemorrhage † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	0/215 (0%)	1/215 (0.47%)
# events				
General disorders				
Chest pain † ^A				
# participants affected/at risk	1/222 (0.45%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Hepatobiliary disorders				

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
Cholecystitis † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Cholelithiasis † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Immune system disorders				
Allergy to arthropod sting † A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				
Infections and infestations				
Appendicitis † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Bronchitis † ^A				

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Erysipelas † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Herpes zoster † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	1/215 (0.47%)	0/215 (0%)
# events				
Infective exacerbation of chronic obstructive airways diseas † ^A				
# participants affected/at risk	0/222 (0%)	2/217 (0.92%)	0/215 (0%)	0/215 (0%)
# events				
Influenza † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	0/215 (0%)	1/215 (0.47%)
# events				
Lower respiratory tract infection † ^A				

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Pneumonia † ^A				
# participants affected/at risk	2/222 (0.9%)	2/217 (0.92%)	3/215 (1.4%)	2/215 (0.93%)
# events				
Pneumonia primary atypical † ^A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				
Sinusitis † ^A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				
Soft tissue infection † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	1/215 (0.47%)	0/215 (0%)
# events				
Injury, poisoning and procedural complications				

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
Ankle fracture † ^A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				
Facial bones fracture † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	1/215 (0.47%)	0/215 (0%)
# events				
Foot fracture † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Hip fracture † ^A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				
Meniscus lesion † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Wrist fracture † ^A				
# participants affected/at	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
risk				
# events				
Investigations				
Electrocardiogram T wave inversion † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Musculoskeletal and connective tissue disorders				
Patellofemoral pain syndrome † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Rotator cuff syndrome † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Neoplasms benign, malignant and unspecified (incl cysts				

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
and polyps)				
Benign gastric neoplasm † ^A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				
Lung adenocarcinoma † ^A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				
Malignant neoplasm of ampulla of Vater † ^A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				
Prostate cancer † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	1/215 (0.47%)	0/215 (0%)
# events				
Tongue neoplasm malignant stage unspecified † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	0/215 (0%)	1/215 (0.47%)
# events				

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
Nervous system disorders				
Cerebrovascular accident † A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				
Haemorrhagic stroke † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Spinal epidural haemorrhage † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	1/215 (0.47%)	0/215 (0%)
# events				
Syncope † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	0/215 (0%)	1/215 (0.47%)
# events				
Transient ischaemic attack † A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	0/215 (0%)	1/215 (0.47%)

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
risk				
# events				
Psychiatric disorders				
Bipolar disorder † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	1/215 (0.47%)	0/215 (0%)
# events				
Delirium † ^A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				
Renal and urinary disorders				
Renal failure acute † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	1/215 (0.47%)	0/215 (0%)
# events				
Respiratory, thoracic and mediastinal disorders				
Chronic obstructive pulmonary disease † ^A				
# participants affected/at	2/222 (0.9%)	7/217 (3.23%)	6/215 (2.79%)	1/215 (0.47%)

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
risk				
# events				
Pleural effusion † ^A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				
Pneumothorax † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	1/215 (0.47%)	0/215 (0%)
# events				
Respiratory arrest † ^A				
# participants affected/at risk	0/222 (0%)	0/217 (0%)	0/215 (0%)	1/215 (0.47%)
# events				
Respiratory failure † ^A				
# participants affected/at risk	0/222 (0%)	1/217 (0.46%)	0/215 (0%)	0/215 (0%)
# events				
Vascular disorders				
Femoral artery occlusion † ^A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
# events				
Iliac artery occlusion † ^A				
# participants affected/at risk	1/222 (0.45%)	0/217 (0%)	0/215 (0%)	0/215 (0%)
# events				

† Indicates events were collected by systematic assessment.

A Term from vocabulary, MedDRA

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 3%

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
Total # participants affected/at risk	75/222 (33.78%)	63/217 (29.03%)	66/215 (30.7%)	62/215 (28.84%)
Gastrointestinal disorders				
Diarrhoea † ^A				
# participants affected/at risk	8/222 (3.6%)	4/217 (1.84%)	1/215 (0.47%)	5/215 (2.33%)
# events				
Infections and infestations				
Lower respiratory tract				

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
infection † ^A				
# participants affected/at risk	1/222 (0.45%)	8/217 (3.69%)	3/215 (1.4%)	2/215 (0.93%)
# events				
Nasopharyngitis † ^A				
# participants affected/at risk	6/222 (2.7%)	14/217 (6.45%)	16/215 (7.44%)	17/215 (7.91%)
# events				
Upper respiratory tract infection † ^A				
# participants affected/at risk	17/222 (7.66%)	6/217 (2.76%)	10/215 (4.65%)	14/215 (6.51%)
# events				
Musculoskeletal and connective tissue disorders				
Back pain † ^A				
# participants affected/at risk	10/222 (4.5%)	8/217 (3.69%)	6/215 (2.79%)	11/215 (5.12%)
# events				
Pain in extremity † ^A				
# participants affected/at risk	1/222 (0.45%)	7/217 (3.23%)	6/215 (2.79%)	4/215 (1.86%)

	UMEC 125 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD	TIO18 µg QD
# events				
Nervous system disorders				
Headache † ^A				
# participants affected/at risk	25/222 (11.26%)	21/217 (9.68%)	20/215 (9.3%)	15/215 (6.98%)
# events				
Respiratory, thoracic and mediastinal disorders				
Cough † ^A				
# participants affected/at risk	14/222 (6.31%)	5/217 (2.3%)	8/215 (3.72%)	6/215 (2.79%)
# events				
Oropharyngeal pain † ^A				
# participants affected/at risk	8/222 (3.6%)	3/217 (1.38%)	6/215 (2.79%)	3/215 (1.4%)
# events				
Vascular disorders				
Hypertension † ^A				
# participants affected/at risk	9/222 (4.05%)	1/217 (0.46%)	4/215 (1.86%)	7/215 (3.26%)
# events				

† Indicates events were collected by systematic assessment.

A Term from vocabulary, MedDRA

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.

Limitations and Caveats:

Results Point of Contact:

Name/Official Title: GSK Response Center

Organization: GlaxoSmithKline

Phone: 866-435-7343

Email: